PTC Therapeutics Launches 9th Annual STRIVE™ Awards Program to Fund Initiatives Benefitting the Duchenne Muscular Dystrophy Community

Rhea-AI Summary

PTC Therapeutics (PTCT) announced the launch of its ninth STRIVE™ awards program aimed at funding initiatives for the Duchenne Muscular Dystrophy (Duchenne) community. Submissions are due by March 17, 2023, with projects focusing on Innovation and Transition to Adulthood. Since its inception in 2015, STRIVE has supported 39 initiatives across 20 countries, addressing the needs of Duchenne patients who now live longer due to improved treatments. This year’s recipients will be announced in September, continuing PTC's 25-year commitment to support the Duchenne community.

Positive

• Launch of the ninth STRIVE™ awards program to fund Duchenne initiatives.
• Focus on Innovation and Transition to Adulthood supports a critical need in the community.
• 39 initiatives funded since 2015, enhancing awareness and support for Duchenne patients.

Negative

• None.

- 2023 Program to Focus on Innovation and Transition to Adulthood Initiatives –

- Submissions Due March 17, 2023 -

SOUTH PLAINFIELD, N.J., Jan. 17, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the ninth annual STRIVE™ awards program. Through this program, PTC awards grants to patient advocacy organizations who are committed to developing initiatives that address the needs of the Duchenne Muscular Dystrophy (Duchenne) community. Organizations may submit entries to fund 2023 projects focused on one of two categories: Innovation or Transition to Adulthood.

"For 25 years, we have remained committed to supporting the Duchenne community," said Mary Frances Harmon, Senior Vice President, Corporate Relations, PTC Therapeutics. "We created STRIVE in 2015 to encourage and reward innovation by patient advocacy organizations by supporting their unique ideas and programs that help to address the needs of people living with Duchenne around the world. We are excited to see the 2023 submissions."

Duchenne is the most common form of muscular dystrophy among children and, until recently, those living with Duchenne usually did not live beyond their teens¹; however, improvements in the treatment and management of Duchenne have increased life expectancy, and now many Duchenne patients are living well into their 30s and 40s.^1,2 As a result, there is an increasing need for psychosocial support for the Duchenne community.³ The future for people living with Duchenne is broadening and innovative programs that provide support and encourage independence are of infinite value.

Since its inception, STRIVE has supported 39 patient-focused initiatives from not-for-profit organizations in 20 countries. Past STRIVE grant recipients have developed programs to support the transition from adolescence to adulthood, improved access to diagnosis and treatment, supplied vital physical and social care to those affected and their caregivers, created career opportunities for adults with Duchenne and raised awareness of the disease in educational, public, and healthcare settings.

The 2023 application process is now open and the deadline for submissions is March 17, 2023. Eligible organizations may submit proposals through an application form available on PTC's STRIVE website. The 2023 STRIVE grant award recipients will be announced in September.

About the STRIVE™ Awards Program

PTC launched the Strategies to Realize Innovation, Vision, and Empowerment (STRIVE) Awards program in 2015 to support initiatives that benefit the Duchenne community by increasing awareness, diagnosis and education and fostering the development of future patient advocates. Each year, an independent panel of external experts with knowledge in rare diseases, patient advocacy and funding initiatives judges the entries for innovation, vision, and empowerment. For more information about the program and support with writing grant entries, please visit the STRIVE website.

About Duchenne Muscular Dystrophy

Primarily affecting males, Duchenne muscular dystrophy (Duchenne) is a rare and fatal genetic disorder that results in progressive muscle weakness from early childhood and leads to premature death in the mid-twenties due to heart and respiratory failure. It is a progressive muscle disorder caused by the lack of functional dystrophin protein. Dystrophin is critical to the structural stability of all muscles, including skeletal, diaphragm, and heart muscles. Patients with Duchenne can lose the ability to walk as early as age ten, followed by loss of the use of their arms. Duchenne patients subsequently experience life-threatening lung complications, requiring the need for ventilation support and heart complications in their late teens and twenties.

More information regarding Duchenne is available through the Muscular Dystrophy Association and the Parent Project Muscular Dystrophy. Additionally, information and resources are available at www.duchenneandyou.com.

About PTC

PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to innovate to identify new therapies and can globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines. Our mission is to provide access to best-in-class treatments for patients who have little to no treatment options. The company's strategy is to leverage its strong scientific and clinical expertise and global commercial infrastructure to bring therapies to patients.  We believe this allows us to maximize value for all our stakeholders. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Instagram, Facebook, Twitter, and LinkedIn. 

For More Information:

Media:
Jeanine Clemente
(908) 912-9406
jclemente@ptcbio.com

Patient Organizations:
Mary Frances Harmon
(973) 960-5227
mharmon@ptcbio.com

References

1. Muscular Dystrophy Association. Duchenne Muscular Dystrophy (DMD). Available at: https://www.mda.org/disease/duchenne-muscular-dystrophy Accessed: December 2022
2. National Institute of Neurological Disorders and Stroke. Muscular Dystrophy: Hope Through Research. Available at: https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Hope-Through-Research/Muscular-Dystrophy-Hope-Through-Research#3171_9 Accessed: December 2022
3. Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018; 17:251–267.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/ptc-therapeutics-launches-9th-annual-strive-awards-program-to-fund-initiatives-benefitting-the-duchenne-muscular-dystrophy-community-301722086.html

SOURCE PTC Therapeutics, Inc.

FAQ

What is the STRIVE awards program launched by PTC Therapeutics (PTCT)?

The STRIVE awards program funds initiatives that benefit the Duchenne Muscular Dystrophy community, focusing on innovation and adult transition.

When are submissions due for the 2023 STRIVE awards program?

Submissions for the 2023 STRIVE awards program are due by March 17, 2023.

How many initiatives has the STRIVE program supported since its inception?

The STRIVE program has supported 39 initiatives across 20 countries since its inception in 2015.

What will the STRIVE award recipients be announced?

The 2023 STRIVE award recipients will be announced in September.

What is the significance of the STRIVE program for the Duchenne community?

The STRIVE program addresses critical needs such as psychosocial support and improved access to care for Duchenne patients.